Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

ClinicalTrials.gov ID: NCT05739942

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05739942. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Radiotherapy (RT) and Temozolomide (TMZ) in Subjects With Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \[68Ga\]Ga-NeoB and characterize its uptake in the tumor area.

Study identification

NCT ID: NCT05739942
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 42 participants

Conditions and interventions

Conditions

Newly Diagnosed and Recurrent Glioblastoma

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 15, 2024 (Actual)
Primary completion: Aug 10, 2027 (Estimated)
Completion: Aug 10, 2027 (Estimated)
Last update posted: Sep 30, 2026

2024 – 2027

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
University of California LA	Los Angeles	California	90095	—
University of Colorado Denver	Aurora	Colorado	80045	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Memorial Sloan Kettering Cancer Ctr	New York	New York	10065	—
Univ Hosp Cleveland Medical Center	Cleveland	Ohio	44106-5028	—
Uni of Utah Huntsman Cancer Inst	Salt Lake City	Utah	84103	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05739942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 30, 2026 · Synced Nov 15, 2026